Meeting the challenge: Prevention of pneumococcal disease with conjugate vaccines;Al encuentro del reto: Prevención de la enfermedad neumocócica con vacunas conjugadas

Salud Publica de Mexico

Volumn 43, Issue 4, 2001, Pages 352-367

  Echaniz Aviles I G ^a   Solorzano Santos F ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Infant; Pneumococcal infections; Streptococcus pneumoniae; Vaccines

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; DEVELOPING COUNTRY; HUMAN; OUTCOMES RESEARCH; PUBLIC HEALTH; REVIEW; RISK BENEFIT ANALYSIS; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 17344389994     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0036-36342001000400012     Document Type: Review

References (127)

1. A nationwide prospective surveillance study in Israel to document pediatric invasive infections, with an emphasis on Haemophilus influenzae type b infections
2. Pneumococcal disease and the role of conjugate vaccines
3. The enduring pneumococcus: Unfinished business and opportunities for the future
4. Pneumococcal vaccines: WHO Position Paper
5. Potential interventions for the prevention of childhood pneumonia: Geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children - Implications for vaccine strategies
6. Etiology of severe pneumonia in children in developing countries
7. Invasive pneumococcal disease in the immunocompromised host
8. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults
9. Bacteraemic pneumococcal infections in Southern Sweden 1981-96: Trends in incidence, mortality, age-distribution, serogroups and penicillin- resistance
10. Incidence of invasive pneumococcal disease and distribution of capsular types of pneumococci in Denmark, 1989-94
11. Invasive Streptococcus pneumoniae infection in Latin American children: Results of the Pan American Health Organization Surveillance Study
12. Capsular types of Streptococcus pneumoniae causing disease in children from Mexico City
13. Antimicrobial susceptibilities and capsular types of invasive Streptococcus pneumoniae isolated in children in Mexico City
14. Prevalence of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated from Brazilian children with invasive infections. Regional System for Vaccines in Latin America
15. Pan American Health Organization epidemiological surveillance network for Streptococcus pneumoniae
16. Distribution of capsular types and penicillin-resistance of strains of Streptococcus pneumoniae causing systemic infections in Argentinian children under 5 years of age
17. Distribution of capsular types and antimicrobial susceptibility of invasive isolates of Streptococcus pneumoniae in Colombian children
18. The significance of pneumococcal types
19. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III
20. A brief history of the pneumococcus in biomedical research: A panoply of scientific discovery
21. Streptococcus pneumoniae: Virulence factors, pathogenesis, and vaccines
22. Six newly recognized types of Streptococcus pneumoniae
23. Serogroup-specific epidemiology of Streptococcus pneumoniae: Associations with age, sex, and geography in 7,000 episodes of invasive disease
24. The bacteriology of the nasopharynx in childhood
25. Marked differences in pneumococcal carriage and resistance patterns between day care centers located within a small area
26. Epidemiologic studies of Streptococcus pneumoniae in infants: Acquisition, carriage, and infection during the first 24 months of life
27. Pneumococcal vaccines
28. Molecular and cellular biology of pneumococcal infection
29. Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients
30. Previous antibiotic consumption and other risk factors for carriage of penicillin-resistant Streptococcus pneumoniae in children
31. Susceptibility of pneumococci to nine antibiotics
32. Antimicrobial resistance in Streptococcus pneumoniae: An overview
33. Three predominant clones identified within penicillin-resistant South African isolates of Streptococcus pneumoniae
34. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type I-infected children
35. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: Update (1990 to 1996)
36. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary
37. In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia
38. The incidence of penicillin-resistant pneumococci in the Slovak Republic
39. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study
40. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
41. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States
42. Penicillin resistance in laboratory isolates of Streptococcus pneumoniae, in Western Australia, 1990-1994
43. Increase in penicillin resistance rates in Belgium due to clonal spread of a penicillin-resistant 23F Streptococcus pneumoniae strain
44. Multidrug-resistant Streptococcus pneumoniae in Poland: Identification of emerging clones
45. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998
46. Capsular transformation of a multidrug-resistant Streptococcus pneumoniae in vivo
47. Acquisition of new capsular genes among clinical isolates of antibiotic- resistant Streptococcus pneumoniae
48. Antimicrobial resistance in Streptococcus pneumoniae: A South African perspective
49. Serotypes and clones of antibiotic-resistant pneumococci
50. Spread of the Spanish multi-resistant serotype 23F clone of Streptococcus pneumoniae to Seoul, Korea
51. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae
52. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s
53. Penicillin-binding proteins of multiply antibiotic-resistant South African strains of Streptococcus pneumoniae
54. Interspecies recombinational events during the evolution of altered PBP 2x genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae
55. Origin and molecular epidemiology of penicillin-binding-protein- mediated resistance to beta-lactam antibiotics
56. A two-component signal-transducing system is involved in competence and penicillin susceptibility in laboratory mutants of Streptococcus pneumoniae
57. A novel resistance mechanism against beta-lactams in Streptococcus pneumoniae involves CpoA, a putative glycosyltransferase
58. Non-Penicillin-Binding protein mediated high-level penicillin and cephalosporin resistance in a Hungarian clone of Streptococcus pneumoniae
59. Predominance of the multiresistant 23F international clone of Streptococcus pneumoniae among isolates from Mexico
60. Penicillin-resistant Streptococcus pneumoniae in Colombia: Presence of international epidemic clones
61. The apparent importation of penicillin-resistant capsular type 14 Spanish/French clone of Streptococcus pneumoniae into Uruguay in the early 1990s
62. Penicillin-resistant Streptococcus pneumoniae in Argentina: Frequent occurrence of an internationally spread serotype 14 clone
63. Molecular epidemiologic characterization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin-American countries: An overview
64. Epidemiology of invasive childhood pneumococcal infections in Israel
65. Etiology and treatment of pneumonia
66. Etiology and treatment of community-acquired pneumonia in ambulatory children
67. Diagnosis and management of acute sinusitis
68. Sinusitis overview
69. Sinusitis
70. Childhood sinusitis: Pathophysiology, diagnosis and treatment
71. Otitis media
72. The problem of resistant bacteria for the management of acute otitis media
73. Is the pneumococcus the one and only in acute otitis media?
74. Clinical significance of resistant organisms in otitis media
75. Otitis media: The chinchilla model
76. Chronic otitis media with effusion
77. Otitis media in children
78. Cost-effectiveness considerations in otitis media treatment
79. World Development Report: Investing in Health
80. The United States needs a national vaccine authority
81. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups
82. Pneumococcal vaccination for older adults: The first 20 years
83. Pneumococcal conjugate vaccination for adults: Why it's important for children
84. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly
85. The clinical effectiveness of pneumococcal vaccine in the elderly
86. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study
87. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations
88. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
89. Issues and challenges: Pneumococcal vaccination in pediatrics
90. The dinical effectiveness of pneumococcal vaccination: A brief review
91. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding
92. Invasive disease due to Haemophilus influenzae type b during the first six years of general vaccination of Swedish children
93. Immunization coverage among predominantly Hispanic children, aged 2-3 years, in central Los Angeles
94. Rational design of conjugate vaccines
95. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: Implications for development of a conjugate vaccine
96. New challenges in the development of a conjugate pneumococcal vaccine
97. The contribution of specific pneumococcal serogroups to different disease manifestations: Implications for conjugate vaccine formulation and use, part II
98. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I
99. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants
100. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens
101. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine
102. 197 in United States infants
103. 197 conjugate vaccine in infants and toddlers
104. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
105. Efficacy of a pneumococcal conjugate vaccine against acute otitis media
106. Technical report: Prevention of pneumococcal infections, including the use of pneumococcal coniugate and polysaccharide vaccines and antibiotic prophylaxis
107. Preventing pneumococcal disease among infants young and children: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
108. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children
109. Childhood vaccination against pneumococcal otitis media and pneumonia: An analysis of benefits and costs
110. The hidden costs of infant vaccination
111. Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharide
112. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae
113. Carriage of pneumococci after pneumococcal vaccination
114. Effect of a 9-valent vaccine conjugated to CRN197 (PncCRM9) on nasopharyngeal (NP) carriage of vaccine type and non-vaccine type S. pneumoniae (Pnc) strains among day care center (DCC) attendees
115. Pneumococcal proteins PspA and PspC: Their potential for use as vaccines
116. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection
117. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae
118. Bacterial vaccines and serotype replacement: Lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae
119. Pneumococcal conjugate vaccines
120. Antibiotic therapy in febrile children: "Best-laid schemes"
121. Limiting the spread of resistant, pneumococci: Biological and epidemiologic evidence for the effectiveness of alternative interventions
122. Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae
123. Pneumococcal vaccines for children: An update
124. Streptococcus pneumoniae: At the threshold of the 21st century